EU’s Joint Regulatory/HTA System Praised, But Improvements Needed
Access To New Drugs Is Still Problematic In Some Countries
Panelists at the virtual DIA Europe 2020 conference heard some good news about progress with the EU’s parallel consultation system for scientific advice, and some not so good news about continuing differences in health technology assessments at national level across Europe.
You may also be interested in...
The DIA Europe 2020 conference heard from regulators and health technology assessment bodies about the problems that can arise over poorly defined patient populations and a lack of comparator data when making reimbursement decisions.
Participants at a workshop on the EU’s proposed Pharmaceutical Strategy discussed affordability and drug shortages and called for more urgency on the draft HTA regulation.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.